Perampanel

Drug Profile

Perampanel

Alternative Names: E-2007; ER-155055-90; Fycompa

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ESTEVE
  • Class Analgesics; Antiepileptic drugs; Nitriles; Pyridines; Pyridones; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Seizures
  • Phase II Epilepsy
  • Discontinued Migraine; Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 28 Jul 2017 Launched for Partial epilepsies (In adults, In adolescents, Monotherapy) in USA (PO)
  • 27 Jul 2017 Registered for Partial epilepsies (In adults, In adolescents, Monotherapy) in USA (PO)
  • 10 May 2017 Phase-III clinical trials in Partial epilepsies (Monotherapy) in Japan (PO) before May 2017 (Eisai pipeline, May 2017) (NCT03201900)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top